Abstract
Nanotechnology-based products show the tremendous potential to change the course of diagnostics and therapy. Numerous nanosystems are already available in the market and hundreds of products are currently in different stages of the preclinical and clinical development. Although in the last two decades, several nanoformulations have been approved in the market, the guidelines are not very clear and a closer collaboration between regulatory agencies is required. The main hurdle to generate regulation of these nanopharmaceuticals is related to their properties/characteristics. Different regulatory bodies across the globe have released their guidelines to address nanopharmaceuticals aspects that are known to have a profound effect to introduce new nanoformulation in the market. This chapter deals with all these regulatory guidelines need to be followed for the development of nanopharmaceuticals.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Nanotechnology Applications for Cancer Chemotherapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
